Roger Perlmutter, 2016 Institute for Systems Biology via Youtube
June 9, 2020 04:45 PM EDTUpdated June 9, 10:05 PM
R&D

King Keytru­da floun­ders in an­oth­er piv­otal can­cer study. And that may spur doubts about Mer­ck­'s stay­ing pow­er

John Carroll

Editor & Founder

The king of the PD-(L)1 class is see­ing a few cracks start to ap­pear in the crown.

Mer­ck re­port­ed Tues­day evening that its Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

A service from the Financial Times